| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3c2e77f8dfda692ca527454d23ecc03 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-907
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0634
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 |
| filingDate |
2019-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cca41b049fc1a4bcd7ec073fd083813f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cfeb5d8ba064b2fa71beda3896994fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_856147826bb26e23b1b5b4613350ab5a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37c36f8c1b3f20b6dc4df0e4d22c1f24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c22114deef1de767f490d2508e38150
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b420069c5724fd7a4b4db2cdca23f17a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41e7628fbda966f18fb1dbb79ce32516 |
| publicationDate |
2021-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3765040-A2 |
| titleOfInvention |
Lymphohematopoietic engineering using cas9 base editors |
| abstract |
Provided herein are methods and systems for targeted gene disruption (knock-out, missense mutation) and targeted gene knock-in in mammalian cells using base editors and guide RNAs (gRNAs) designed to target splice acceptor-splice donor sites. Also provided herein are universally acceptable genetically engineered cells comprising targeted disruptions in immunotherapy-related genes and comprising a CAR/TCR for therapeutic applications. |
| priorityDate |
2018-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |